Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04211259 · ClinicalTrials.gov registry record · Early Phase 1
Loratadine for the Reduction of G-CSF Induced Bone Pain in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization
A Early Phase 1 study, sponsored by Rutgers, The State University of New Jersey.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 70
- Enrollment target
NCT04211259: Recruiting Early Phase 1 study, sponsored by Rutgers, The State University of New Jersey.
NCT04211259 is a Early Phase 1 study that is actively recruiting participants, run by Rutgers, The State University of New Jersey. The registered enrollment target is 70 participants, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (32% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04211259, a Early Phase 1 study, is actively recruiting participants, sponsored by Rutgers, The State University of New Jersey.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 70 participants
- Enrollment target
Study Summary
This early phase I trial studies how well loratadine works in reducing granulocyte-colony stimulating factor (G-CSF) induced bone pain in patients with multiple myeloma who are undergoing stem cell mobilization. Loratadine is an antihistamine that may help to reduce or control bone pain during the process of stem cell collection in patients with multiple myeloma.
Primary Outcome
Pain severity will be measured at baseline and following treatment using a 10-point scale, with higher numbers indicating greater degrees of pain. Will compare the difference in mean pain level for each group following therapy.
Interventions
- OTHER Placebo
- OTHER Questionnaire Administration
- DRUG Loratadine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2022-04-18 |
| Est. Completion | 2027-06-30 |
| Phase | Early Phase 1 |
What NCT04211259 shows while recruiting
NCT04211259 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 70 participants, a relatively small participant target, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (32% higher).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT04211259 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04211259 about?
NCT04211259 is a clinical study titled "Loratadine for the Reduction of G-CSF Induced Bone Pain in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization". This early phase I trial studies how well loratadine works in reducing granulocyte-colony stimulating factor (G-CSF) induced bone pain in patients with multiple myeloma who are undergoing stem cell mobilization. Loratadine is an antihistamine that may help to reduce or control bone pain during the p...
What is the current status of trial NCT04211259?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 70 participants. The study started on 2022-04-18. Estimated completion is 2027-06-30.
What interventions are being tested in trial NCT04211259?
The interventions under investigation include: Placebo (OTHER), Questionnaire Administration (OTHER), Loratadine (DRUG).
Who is sponsoring clinical trial NCT04211259?
This trial is sponsored by Rutgers, The State University of New Jersey, which has 413 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04211259's enrollment target sits among peer trials
70 339th of 2000 higher than 1,647 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00969111 · 70 participants · NA
Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy
- NCT01712620 · 70 participants · Phase 2
Spironolactone for Pulmonary Arterial Hypertension
- NCT02143830 · 70 participants · Phase 2
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
- NCT02601339 · 70 participants
NIRS Monitoring in Premature Infants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI